Pharma Focus Asia
KP - Sustainable Packaging Solutions

Novo Nordisk Breaks Ground on $2 billion Production Facility in Clayton, North Carolina


Novo Nordisk broke ground on its new 2 billion US dollar production facility in Clayton, North Carolina.


The facility will produce active pharmaceutical ingredients (API) for a range of Novo Nordisk's current and future GLP-1 and insulin products. Once fully operational in 2020, Clayton will ensure production capacity for diabetes care products in the US for the decade ahead.

The new site is situated adjacent to Novo Nordisk's existing 42,000 m2 facility which assembles and packages FlexPen® and FlexTouch® prefilled insulin devices for the US market. The expansion is expected to create close to 700 new jobs and Novo Nordisk expects to create a significant employment effect during the construction period with up to 2,500 people working on the project at its peak.


Company NameNovo Nordisk
LocationClayton, North Carolina
TypeNew Production Facility
Estimated Investment$1.8 Billion
Jobs to be created700 Jobs
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024Equinix accelerated medical research...CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?